[RFC] Utilizing Nexus Capital Pool in Morpho

Last call for comments, review period: 19–25 June
Snapshot signaling vote: Open for voting between 26 June until 3 July.


Nexus Capital Pool liquidity is intended to be utilised in productive venues, following the investment philosophy described here and Nexus Community leanings expressed on various posts in the forum.
This RFC proposes allocating 5% of the 96,956 ETH (i.e. 3.35% of the Total Capital Pool Liquidity) in Morpho-Aave V2/V3 to earn interest from lending ETH while maintaining directional long exposure to ETH

About Morpho


Morpho is a lending protocol, the third biggest on Ethereum after Aave and Compound, with +$700m currently deposited.
Morpho improves the capital efficiency of positions on lending pools such as Aave and Compound by matching lenders and borrowers peer-to-peer, strictly improving APY on both sides. While offering superior rates, Morpho preserves the same user experience, liquidity, and parameters as the underlying lending protocol.

Morpho has raised $20M, with the latest $18M funding round led by a16z crypto and Variant.

Morpho value proposition

On Morpho, depositors/borrowers can receive two rates:

  • Liquidity is matched peer to peer: users receive an improved rate, called the p2pRate
  • Liquidity is not yet matched (peer to pool): users receive the APY of the underlying pool Indeed when a Morpho user is not matched, Morpho will tap into the liquidity of the underlying lending pool. In this case, Morpho redistributes all the pool APY + all pool liquidity rewards.

If there are not enough peers to match the total amount that a user deposited/borrowed, it is possible to have some funds matched and the rest sourced through the pool. In this case, the liquidity that matches P2P will earn the P2P APY while the rest of the liquidity will earn the pool’s APY. Either way, users always have the incentive to deposit in Morpho as they’re getting better/equal rates equal to one of the underlying protocols alongside MORPHO tokens that are currently distributed

Using Messari’s data from Q1-23, Morpho-Aave outperforms the underlying pools by:

  • +42.85% on the DAI market
  • +29.03% on the USDC market
  • +42.56% on the wETH market

Morpho matches users Peer to Peer using a matching engine. Learn more

A robust and conservative strategy for Nexus

Nexus philosophy of investment

Considering ETH as cash, Nexus defines investment risk relative to holding ETH. From this ETH base, Nexus introduces three risk buckets for its investment strategy: lower, medium, and higher risk. stETH is used as the benchmark for yield and the lower risk bucket will consist mostly of ETH2 staking. The lower risk bucket has a max allocation ranging from 30% to 80%.

Morpho risks profile: lower risk

Type of risk Risk level
Illiquidity Risk LOW
Morpho position can be withdrawn instantly, in a block’s time. Morpho is as liquid as the underlying borrowable lending pool. If you can immediately borrow billions on Aave - Open Source Liquidity Protocol (resp. Compound), you will be able to immediately withdraw/borrow billions on Morpho-Aave (resp. Compound).
Basis Risk LOW
Supplying ETH on Morpho is ETH denominated
Protocol Risk (DeFi Safety Score) LOW
Morpho is the number 1 out of 300+ projects on https://defisafety.com/appwith a 98% mark
Liquidation Risk LOW
Morpho replicates on-chain the different risk parameters of the underlying lending pool, like the oracles, collateral factors, close factors, etc.
Leverage LOW
Supply ETH on Morpho doesn’t involve leverage
Counterparty Risk LOW
Morpho is permissionless and non-custodial. Aave is permissionless and non-custodial
Economic risk LOW
Risk of attacks on collateral + the risk of morpho being liquidated, however, As long as liquidators perform liquidations, Morpho cannot be liquidatable.

Morpho belongs to the lower risk bucket, with the same risk parameters as Aave but a strict APY improvement.

Proposed allocation strategy in Morpho

Given the max allocation rules exposed earlier and the degree of risk incurred by Morpho, an initial deposit of 5% of the 96,960 ETH (i.e. 4.848 ETH or 3.35% of the Total Capital Pool Liquidity) into Morpho-Aave is proposed. This amount would be earning improved rewards from lending ETH while leaving substantial room for higher yield/riskier strategies.

Morpho exemplified different allocation scenarios below to give perspective to the community and help make them an informed decision.

Projected Returns for the Capital Pool

ETH being an oversubscribed market on the demand side, Nexus ETH allocation would be 100% matched peer-to-peer, thus enjoying improved rates. Using data from the last 5-months), the average P2P rate (supply rate) on Morpho Aave is 2.48% (3.09% on 05/17/23)
Nexus can then expect to grow its treasury by the following:

MORPHO Liquidity Incentives

Morpho currently offers liquidity incentives in the form of the MORPHO token, distributed based on liquidity provided to the protocol across multiple “ages” subdivided into claimable periods via Merkle Tree reward distribution. The MORPHO token is not transferrable as of now.

Diversification option from holding Liquid Staking Tokens

Morpho-Aave is the best place to lend ETH with reduced exposure to LSTs. If LSTs depeg/get slashed a lot, borrowers get liquidated and ETH is safe. If liquidators fail, there is however a dependency).

In that sense, supplying ETH on Morpho offers diversification from validator and slippage risks that accompany holding Liquid Staking Tokens. Indeed, Morpho enables enhanced “liquidity”: if the unstaking queue is full, it may be better to have a position on Morpho to withdraw liquidity rather than LSTs. This is even more valid for large positions that would have a large slippage to exit

Risks, tracking, and decentralization

Aave/Compound risk frameworks

Morpho being built on top of Aave/Compound, it inherits their high-quality code as well as their risks. Today, the risks related to the Aave platform are:

  • Smart contract risks (risks of a bug within the protocol code)
  • Economic risk (risks on the collateral liquidation process)

In order to minimize smart contract risks:

  • Aave V2 holds security at its core with audits by Consensys Diligence, CertiK and Certora as detailed in Security & Audits.
  • Aave V3 holds security at its core with V3 audits by Trail of Bits, ABDK, Peckshield, OpenZeppelin, [SigmaPrime] and formal verification by Certora further detailed in Security & Audits
  • Aave has an ongoing bug bounty campaign live and running.
  • The Compound protocol has been reviewed & audited by Trail of Bits and OpenZeppelin.
  • The Compound protocol was developed with specifications of security principles, and formally verified by Certora using Certora ASA (Accurate Static Analysis), which is integrated into Compound’s continuous integration system.

In order to minimize economic risks:

  • Liquidators receive discounted collateral in return (also known as the liquidation bonus) which creates incentives for them to liquidate. On both protocols, the liquidator ecosystem is extremely competitive and active
  • An Aave Market Risk Assessment has been produced by the quantitative modeling team of Gauntlet Networks which was then reviewed after the CRV event in 11/23. Aave V1, V2, and the Safety Module have been stress tested via agent-based simulation. The simulations show the model is currently able to remain solvent under extreme market conditions, showing appropriate risk management. As a result, Gauntlet Network provided some parameter suggestions to further reduce the risk of insolvency.
  • Aave has built an elaborate due diligence process, developed by the Risk Management Team, to assess the risk of currencies supported by Aave. The risk assessment considers market, counter-party, and smart contract risks for the currencies selected for the Aave protocol, aiming to contribute to higher risk standards within DeFi.
  • Aave V3 brings improved risk parameters and new features to protect the protocol from insolvency.
  • Gauntlet has constructed a simulation-based market stress-testing platform to evaluate the economic security of the Compound protocol, as it scales supported assets and volume.

Morpho smart contract risks

Morpho adds extra lines of code compared to a lending pool alone. The top audit firms worldwide performed over 20 audits to limit this additional risk. Morpho Labs team also formally proved part of the protocol in a Yellow-Paper and with the help of Certora.

In more detail:

  • Morpho is the number 1 out of 300+ projects on DeFi Safety with a 98% mark.
  • 20 audits were made on Morpho contracts with top-tier auditors like Trail of Bits, Chainsec, Spearbit, etc. Morpho has a recurrent partnership with Spearbit.
  • Parts of Morpho’s code were formally verified in Why3 or with Certora’s automatic formal prover
  • Morpho’s logic has been formally described in the [Yellow Paper]). The Yellow Paper also proves important properties about the improvement of Morpho compared to underlying lending pools.
  • Morpho has a large $555,555 Immunefi Bounty for smart contracts and front end

Morpho economic risks

As Aave, Morpho bears the risk of the collateral listed on the protocol. Yet, out of the 21 assets listed on Aave, Morpho listed only the 7 considered the safest. Moreover, Morpho replicates the exact same risk parameters of aave (LT, LTV, oracles, …) for each asset.
Moreover, Morpho bears the risk of the health of its position in Aave itself. Liquidations happen when the ‘health factor’ of an account’s total loans is below 1, anyone can make a liquidationCall() to the [Pool] contract and pay back part of the debt owed

However, as proven in the Yellow Paper, Morpho cannot be liquidated if there are working liquidators on the protocol (see the “non-liquidation theorem” references in sections 3.4 and 6.4). The intuition behind it is that an aggregation of healthy positions is a healthy position itself.

A “supply-only” position on Morpho does not require active management as it does not have any liquidation risk. Yet, as in any lending protocol, there is a risk of bad debt. Bad debt occurs for a protocol when accounts that should have been liquidated weren’t (usually because the value of the collateral dropped instantly)

Warden Finance enables tracking the health of the Morpho position taken on the pool.

At the time of writing, Morpho-Aave V2 Health Score is 3.71 which means Morpho is only using 30.99% of its potential borrowing power.

Over the period 10/22-01/23, looking at the comparison of the evolution of the health factor of Morpho-Aave and that of its users combined, Morpho-Aave is healthier and the HF belongs to the 2-9 interval and is trending higher. (See image below). More color on this here

Tracking a position on Morpho

Many tools can help one track positions on Morpho. Specifically, Warden.Finance can also be used also to give a comprehensive overview of a position on Morpho for a given address including:

  • P&L
  • Positions breakdown
  • Health
  • Transactions Simulation tool

A “supply-only” position on Morpho does not require active management as it does not have any liquidation risk. At the time of writing, Morpho-Aave V2 Health Score is 3.71 which means Morpho is only using 30.99% of its potential borrowing power.
Nexus could be monitoring more closely when the Health Ratio of Morpho-Aave V2/V3 position approaches the 1.2-1.5 range and should consider taking action if it ever goes lower and could use HAL to create tailored notification alerts. These numbers are arbitrary and should be used for guidance only.

Morpho organization & Ownership

The Morpho Association is a French nonprofit entity grouping the main contributors and users of the Morpho protocol. Its aim is to develop the Morpho protocol by funding contributors, or by facilitating access to the protocol for users and developers.

Morpho Labs is a core contributor to the Morpho protocol. The company researches and develops new protocols to improve Morpho Additionally, it creates various tools to enhance the functionality and capabilities of Morpho

The Morpho Association deployed the foundational Multisig of the Morpho DAO. The signers include nine association members and require five signatures to approve a transaction, making it a 5/9 Multisig. In June 2022, the association deployed the first instance of the Morpho Protocol and transferred its ownership to the 5/9 Multisig.

This page contains all the relevant signers and modules in the DAO infrastructure.

Morpho’s current Decentralization framework

Decentralization is paramount to Morpho and the Morpho Protocol. The Morpho Association has begun a process of “Progressive Decentralization” via the Gnosis Zodiac Roles tool, to transfer control entirely to the Morpho DAO which is made up of $MORPHO token holders.

Morpho decentralization is a 7-step process currently in stage 4 called “Modular Decentralization and Deploy Delay”. Basically, the ownership of core contracts was transferred from the original 5/9 Morpho DAO Multisig to a new ownerless safe, a Delay Modifer module was deployed, and an Invalidator role was given to the 5/9 multisig.

Future Decentralization of Morpho

The future of Morpho decentralization is a work in progress that include 3 more stages eventually allowing to:

  • Enable Governance Initiated Transactions
  • Revoke Multisig Transactions
  • Depreciate Multisig

Fees, and options


Using Morpho incurs no fees at the moment.

Deposit options

Morpho contemplates two deposit options:

  1. Nexus Treasury can deposit straight into Morpho from the Morpho App or the Safe App Hub, without any additional counterparty risk, for free. In the event of Nexus having specific integration requirements, Morpho would be happy to support the integration work and offer a peer review of the code. We’ve done this in the past with some integrators and was proven extremely useful.
  2. If some complex engineering work is required from Nexus to allocate on Morpho (like an oracle), Morpho is aware of the relationship Nexus has with Enzyme-Finance, the work done on the custom Chainlink oracle reporting the value in ETH back to the Capital Pool, (necessary to keep accounting the assets for possible claims) and other Enzyme features potentially dear to Nexus. Therefore, depositing into Morpho could be done through a vault managed by Enzyme. This option would require integration from the Enzyme side as well as community approval

After the implementation of this initial deposit, we propose a periodic re-assessment of the status of the vault to assess its performance and potential future allocation with the Nexus community

Useful links & metrics

| Protocol | Morpho |
| Strategy | Morpho-Aave v2 - Morpho-Aave v3 |
| App | https://aave.morpho.xyz/ // https://aavev3.morpho.xyz/ |
| Docs | https://docs.morpho.xyz/start-here/homepage |
| Blog | https://medium.com/morpho-labs |
| White Paper | https://whitepaper.morpho.xyz/ |
| Yellow Paper | https://yellowpaper.morpho.xyz/ |
| GitHub | https://github.com/morpho-org |
| Total supply to date | $734,000,000 |

Proposal Status

This RFC was posted on 24 May, and the Investment committee has issued a last call for comments during the next week (19–25 June)!

They want to hear your feedback and comments on this RFC before a non-binding Snapshot signaling vote is opened to gauge member sentiment regarding this RFC proposal.


Edit: @BraveNewDeFi added the proposal status and timelines for review, per @Rei’s message in the thread below.

Edit 2: @BraveNewDeFi updated this RFC to include links to the non-binding Snapshot signaling vote at the start of this RFC and in the Status section.


Hi 0xLoth, thank you for this very detailed proposal!

Morpho is a solid candidate for Nexus to invest capital in a permissionless way. The protocol is #1 on DeFi Safety, has a solid amount of TVL, and overall an interesting risk profile.

However, given the current state of Nexus capital pool, and the low hanging fruit clearly being Ethereum liquid staking derivatives, there are three things that Nexus community should consider :

  1. After the new tokenomics go live, the size of the Capital Pool will shrink. Therefore, we have less ETH available to deploy than it appears.

  2. Does it make sense for Nexus to invest via Morpho now, before allocating to Rocketpool, Stakewise and/or other LSDs?

  3. Does the community want to take on the protocol risk for the expected ~2.5% APY?

My opinion on this is that it makes more sense to first deploy capital in ETH liquid staking derivatives. They offer better returns for a low risk profile.

Nevertheless, I think Morpho is a very valid option to consider on a regular basis. Things like :

  • lower ETH staking yield
  • better ETH lending yield
  • very long staking queue that makes ETH staking unattractive

are all events that may affect the landscape at some point in the future and that would increase Morpho attractiveness to the Nexus community.

Also want to point out that if the investment is approved by governance, it would make most sense to do it through Enzyme. To be able to benefit from the liquidity incentives, it must not be done via the Capital Pool itself as it would be a hassle for Nexus engineering team if one day the MORPHO token become transferrable.


Hi @Gauthier, it’s @Moss from Avantgarde / Enzyme here.

Quick side note on this proposal since we are mentioned along the lines: we have been in touch with @0xloth and the Morpho team for several weeks and have a lot of confidence in their protocol and their whole professional attitude as a team.

We are keen to cooperate with them so - regardless the outcome of this specific proposal - we have decided to build an adapter for Morpho on Enzyme, which will be included in our upcoming audit slot of July 2023.

Once the integration is built and audited, this strategy would eventually become technically actionable whenever the time is right on your side.


Hey @Gauthier ,

Thanks a lot for your valuable feedback and the update on Nexus tokenomics. I understand your assessment of the risk-return tradeoffs of Morpho compared to LSTs and Nexus’s preference to use Morpho through Enzyme.

I want to bring more color to a few aspects:

  • Morpho P2P APY on wETH is trending towards 3% (3.21% at the time of writing) and is likely to stabilize in this area given historical data on spreads and increasing demand for ETH

  • Given the supply/demand flows for ETH Staking (a good proxy of this is the state of the staking queue, the APY of staking will inevitably be diluted over time. To date, the activation length is 45d 12h 6m. On the flip side, Morpho improvements remain constant as the demand for ETH increases and the supply/borrow spread remains. As this unfolds, supplying ETH on Morpho would start to make economic sense

  • LSTs expose the DAO to two liquidity risks: pool depth and pool composition (i.e. ETH/stETH peg) which can lead to significant slippages and principal value cuts. Morpho’s Aave V2 Optimizer debt positions have no exit liquidity constraints and are therefore a valuable “diversification” option

You mentioned in your message “Morpho is a very valid option to consider regularly”. I’m curious to hear more about what you mean by “regular basis” and would love to know how we can support this and help find a suitable investment strategy for the Nexus Community


Thank you very much for your comment @Moss. We share the professionalism sentiment felt throughout our conversations with the Enzyme team. It’s a pleasure to see Nexus’s preference for using Morpho through Enzyme and really see the synergies between Nexus’s capital pool, enzyme infrastructure, and Morpho ETH supply opportunity.
More broadly, there is a strong desire for Morpho to deepen its partnership with Enzyme to push Morpho as a lower-risk option for its strategy offering


Hi @0xloth

Thank you for work put in to this comprehensive & detailed post. :pray:

I think it makes sense to do two Snapshot votes simultaneously:

  1. Do we want to allocate to Morpho: Y/N
  2. Assuming the answer to 1. is yes, how much do we want to allocate, with options TBD.

If successful, we can then proceed to creating an NMIP with implementation details

Happy to work with you to craft appropriate wording & options for the snapshot votes.

Awaiting an update from Enzyme on their RFC & then likely to begin the formal comment process of this proposal, Enzyme and Rocketpool ahead of the snapshot signalling votes. Looks like there will be quite a few things to vote on - trying to coordinate them time-wise so members only have to get their wallets out to vote once :slight_smile:

Personal View
Pretty neutral on this, certainly an attractive proposition, but I also see risk & opportunity cost. Therefore, I’ll just write down some thoughts to add to the conversation

Morpho is undoubtedly impressive from a safety point-of-view, the TVL is high and the yields are non-zero. The relatively low proposed amount also probably works in favour of the proposal, as Aave tends to be one of our major exposures on the liability side. Instant liquidity also a real positive.
MORPHO tokens could potentially result in a very high return down the line if they become liquid.

Some of the considerations (& echoing Gauthier a bit):

  • Opportunity cost Is the ETH better deployed here or in LSDs? Diversification away from ETH staking is certainly a good point, but the yields are somewhat lower.
  • Overall amount deployed. If all current LSD proposals are successful (including the Stakewise one that has been put on hold since May '22 as we await V3), there’s a possibility that ~50% of the capital pool has been allocated to LSDs, with a further 3.35% allocated to Morpho. That would leave about 67,600 ETH un-invested - roughly allowing for the formula-driven MCR, it would leave about 60,000 ETH left over for other uses. There’s also always the option of converting some of the investments back into ETH if it looks like we might need it on hand.
  • Technical integration. We’re unlikely to be able to do the work on our smart contracts to integrate directly given other engineering projects, so Enzyme seems like a good option. Would be helpful to know what the estimate would be from Enzyme/Morpho as to how long the integration would take ahead of a signalling vote.
  • Risks - two main ones for me.
    • Smart contract - 2 protocols involved, and, while both are top-tier in terms of audits, bug bounties, etc. smart contract risk remains non-zero. Bridge use in Aave v3 Portals is scary to me. Is it worth it for 3% APY?
    • Governance - 5/9 multi-sig currently, but all individuals named & some plan to take power away from that multi-sig. Downstream reliance on Aave governance.

Interested to see where the vote goes!


Hey @Rei
Thank you very much for your comment and thorough feedback. Excited about the prospect of putting this to a vote and working with you on the details. I agree with the logic of the Snapshot (Y/N + specs in the case of Y winning).
I understand from your message that Morpho Labs will have to put up the proposal. Do you confirm this?

Some comments regarding your personal feedback:

  • It is true that the yield is slightly lower but, in my opinion, the diversification approach precisely makes a lot of sense here, where half of the capital pool would be used in the same fashion thus exposing this capital to the availability of liquidity constraints and 1:1 parity of LST with ETH at time of exit.
  • As expected, we are already seeing stETH APY decreasing (since the publication of this proposal). The 7d moving average of stETH is now 3.94%
  • I believe Enzyme integration of Morpho will start on the first of July. I’ll let @Moss give more details on this

Excited about moving this forward :butterfly:


Hi @0xloth and @Gauthier, we are also excited to see this proposal moving to Snapshot!

As it pertains to the protocol engineering work for the Morpho<>Enzyme integration, the job is well underway, we are are building the integration as per the ERC-4626 Tokenized Vault Standard.

We are planning to include the adapter in the upcoming audit slot with Chain Security, which is scheduled for 10-14 of July 2023.

If the outcome of the audit is as expected, we’ll then proceed to give it the final touches on the frontend UI and we should be able to accommodate the potential allocation on a dedicated vault by the end of July.

Hope it helps! :tulip::butterfly: :hibiscus:


Hi everyone,

We are aiming to take this proposal to a series of signaling votes on Snapshot. The votes will go live in 7 days (on 2023/06/26).

Please post any additional comments in this thread ahead of the votes on 26th June.

As we approach the back end of this week, the investment committee will coordinate with the original proposer to craft the wording & select options for the signaling votes, also incorporating any new comments from the community.

If the signaling votes show a positive outcome, we will work with the original proposer and the engineering team to put forward an NMPIP that would implement the investment via on-chain vote.


Thanks for the proposal @0xloth !

Outlining my thoughts here.

  • I have a high level concern that the combined smart contract risk of Morpho + Aave + Compound is not worth the yield. This is obviously hard to quantify, but the post smart contract risk yield would appear to be ~0% at best imo.

  • Nexus can’t directly allocate to Morpho without a tailored integration, and we’ve specifically de-prioritised this type of work due to other engineering priorities and the fact we now have Cowswap (to access various liquid token investments). So the only technical option is to access this investment via Enzyme. I’d much prefer to use Nexus smart contract risk budget on Enzyme to access direct ETH staking with specific operators, which is something Nexus can’t access easily without Enzyme. This has a better risk/return profile in my opinion and therefore there is a real opportunity cost.

  • Comparatively, I think the return of this investment option has to be materially higher than ETH staking given the risks involved. Gut feeling is ETH staking + 3-4%.


Hi @Hugh , thank you for your remarks.

I have a high level concern that the combined smart contract risk of Morpho + Aave + Compound

I hear your point, but Morpho’s security practices are highly valued in the space. More than 20 audits in total, ranked first out of 300+ DeFi protocols on DefiSafety, formal verification, formalization of the protocol with yellowpaper.morpho.org, etc.
Not that it is Morpho + Aave or Morpho + Compound, not Morpho + Aave + Compound

Nexus can’t directly allocate to Morpho without a tailored integration

I am not sure to get this. Supplying on Morpho is as simple as supplying to aave. There is a one-click interface Safe and EOA wallets or a simple call to the function supply/withdraw for the smart contracts.
I get the added value of Enzyme for getting Nexus to access direct ETH staking with specific operators, not to interact with Morpho. Especially given the fee they take and the additional counterparty risk.

return of this investment option has to be materially higher than ETH staking given the risks involved. Gut feeling is ETH staking + 3-4%.

The current yield on Morpho plus MORPHO tokens is close to 3%. However, what is most important to me is that supplying ETH to Morpho mitigates Nexus’s exposure to staking risks. Additionally, Morpho provides stronger instant liquidity guarantees for large amounts.

I hope this answers your questions!

1 Like

Thanks for the response.

I understand your points on the security side, and agree Morpho has great practices here. I just think we likely have a different perspective on the likelihood of vulnerability :slight_smile:

On integrations, this is a Nexus specific point. We do not have the technical ability to interact with Morpho contracts (or anything else for that matter apart from Cowswap and Enzyme) from our capital pool.

Snapshot signaling vote

The non-binding signaling vote for this proposal has opened for voting! You will be able to cast your vote from 9am EST / 1pm UTC on Monday (26 June) until 9am EST / 1pm UTC on Monday (3 July).

Voting options

  • Yes: Nexus Mutual should utilize a portion of the Capital Pool in Morpho-Aave V2/V3. It should do so through Enzyme FInance integration for 3.35% of the Capital Pool.
  • No: Nexus Mutual should not utilize a portion of the Capital Pool in Morpho-Aave V2/V3.
  • Abstain

Be sure to review the RFC, cast your vote, and signal your support for the option of your choice!

Hey all, (cc @Hugh @Gauthier @Rei @Moss )
With the vote being live, I thought I could share something relevant for Nexus Stakeholders in the context of this proposal.

Reflecting on the need for a more attractive supply side on Morpho (and trying to close the gap with the stETH APY), we just proposed yesterday to increase Morpho P2P index on the wETH markets (Aave V2 and V3) to attract more supply (demand greatly outpace supply currently).

The APY would move from 2.66% to 3.29%, which is quite a significant bump for pure suppliers (like Nexus) and approaches stETH APY (3.80%)